In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: does timing matter?

[1]  L. Tanoue Cancer Statistics, 2009 , 2010 .

[2]  D. Huntsman,et al.  Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications. , 2010, Gynecologic oncology.

[3]  V. L. Greenberg,et al.  Suberoylanilide hydroxamic acid (SAHA) potentiates paclitaxel-induced apoptosis in ovarian cancer cell lines. , 2010, Gynecologic oncology.

[4]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[5]  Michael Bots,et al.  Rational Combinations Using HDAC Inhibitors , 2009, Clinical Cancer Research.

[6]  A. V. von Bueren,et al.  Acquired vorinostat resistance shows partial cross-resistance to ‘second-generation’ HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities , 2009, Anti-cancer drugs.

[7]  M. Lübbert,et al.  Histone Deacetylase Inhibitors Induce a Very Broad, Pleiotropic Anticancer Drug Resistance Phenotype in Acute Myeloid Leukemia Cells by Modulation of Multiple ABC Transporter Genes , 2009, Clinical Cancer Research.

[8]  S. Modesitt,et al.  A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. , 2008, Gynecologic oncology.

[9]  Anil K Sood,et al.  Early events in the pathogenesis of epithelial ovarian cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Kohno,et al.  Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross‐resistance to a wide range of DNA‐damaging drugs , 2008, Cancer science.

[11]  V. Fantin,et al.  Mechanisms of Resistance to Histone Deacetylase Inhibitors and Their Therapeutic Implications , 2007, Clinical Cancer Research.

[12]  V. L. Greenberg,et al.  In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer. , 2007, Gynecologic oncology.

[13]  Shi-Wen Jiang,et al.  Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells , 2006, Molecular Cancer Therapeutics.

[14]  R. Ohlinger,et al.  Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients , 2006, BMC Cancer.

[15]  P. Bader,et al.  Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells. , 2006, International journal of oncology.

[16]  Y. Bang,et al.  Histone Deacetylase Inhibitors for Cancer Therapy , 2006, Epigenetics.

[17]  J. Issa,et al.  Histone Deacetylase Inhibitors: A Review of Their Clinical Status as Antineoplastic Agents , 2005, Cancer investigation.

[18]  Nishan H Chobanian,et al.  Histone deacetylase inhibitors enhance paclitaxel-induced cell death in ovarian cancer cell lines independent of p53 status. , 2004, Anticancer research.

[19]  J. Arts,et al.  Histone deacetylase inhibitors: from chromatin remodeling to experimental cancer therapeutics. , 2003, Current medicinal chemistry.

[20]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[21]  Ricky W. Johnstone,et al.  Histone-deacetylase inhibitors: novel drugs for the treatment of cancer , 2002, Nature Reviews Drug Discovery.

[22]  Vigushin Dm,et al.  Histone deacetylase inhibitors in cancer treatment. , 2002 .

[23]  D. Vigushin,et al.  Histone deacetylase inhibitors in cancer treatment. , 2002, Anti-cancer drugs.

[24]  P. Marks,et al.  Histone deacetylases and cancer: causes and therapies , 2001, Nature Reviews Cancer.

[25]  V. Richon,et al.  Histone deacetylase inhibitors as new cancer drugs , 2001, Current opinion in oncology.

[26]  P. Marks,et al.  Inhibitors of histone deacetylase are potentially effective anticancer agents. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  P. Marks,et al.  Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. , 2000, Journal of the National Cancer Institute.

[28]  M. Piccart,et al.  Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. , 2000, Journal of the National Cancer Institute.

[29]  J. Workman,et al.  Alteration of nucleosome structure as a mechanism of transcriptional regulation. , 1998, Annual review of biochemistry.

[30]  E. Partridge,et al.  Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). , 1996, Seminars in oncology.